HOTAIRM1 and breast carcinoma: To further validate the clinical relevance of HOTAIRM1 and HOXA1, we analyzed a publicly available clinical in silico dataset comparing 60 paired primary ER+ breast cancer patients to recurred cancer patients following tamoxifen mono-therapy for 5 years (GSE1379).